載入...
Selinexor in relapsed/refractory multiple myeloma
Multiple myeloma (MM) represents an incurable hematologic malignancy. Despite significant advances over the past decade, with the advent of multiple new classes of anti-myeloma agents, including immunomodulatory drugs, proteasome inhibitors and monoclonal antibodies, patients ultimately relapse. Sel...
Na minha lista:
| 發表在: | Ther Adv Hematol |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
SAGE Publications
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7285937/ https://ncbi.nlm.nih.gov/pubmed/32566115 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620720930629 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|